Factor | OR | 95% CI | P value |
Stage III (N=5038), treatment delay (>35 days) | |||
Age at diagnosis (years) | |||
61–70 vs 18–60 | 1.17 | 0.99 to 1.36 | 0.0548 |
71–80 vs 18–60 | 1.52 | 1.29 to 1.80 | <0.0001 |
80+ vs 18–60 | 1.57 | 1.23 to 2.02 | 0.0004 |
History of other cancer | |||
Yes vs no | 1.53 | 1.23 to 1.91 | 0.0003 |
Performance status | |||
1 vs 0 | 1.14 | 0.97 to 1.35 | 0.1124 |
2 vs 0 | 1.11 | 0.86 to 1.43 | 0.4305 |
3+4 vs 0 | 0.62 | 0.41 to 0.93 | 0.0223 |
Missing vs 0 | 1.01 | 0.85 to 1.20 | 0.8864 |
EUS | |||
Yes vs no | 1.39 | 1.16 to 1.66 | 0.0005 |
EBUS | |||
Yes vs no | 1.81 | 1.58 to 2.07 | <0.0001 |
Explorative surgery | |||
Yes vs no | 10.92 | 4.02 to 29.7 | <0.0001 |
Transthoracic biopsy | |||
Yes vs no | 2.24 | 1.72 to 2.90 | <0.0001 |
Unknown vs no | 0.91 | 0.79 to 1.05 | 0.2002 |
Type of therapy | |||
Radiotherapy vs chemoradiotherapy | 2.34 | 1.99 to 2.74 | <0.0001 |
Systemic therapy vs chemoradiotherapy | 1.58 | 1.34 to 1.86 | <0.0001 |
Stage IV (N=5268), treatment delay (>35 days) | |||
Age at diagnosis (years) | |||
61–70 vs 18–60 | 1.16 | 1.01 to 1.34 | 0.0363 |
71–80 vs 18–60 | 1.44 | 1.23 to 1.67 | <0.0001 |
80+ vs 18–60 | 1.79 | 1.32 to 2.42 | 0.0002 |
Performance status | |||
1 vs 0 | 1.07 | 0.92 to 1.25 | 0.3745 |
2 vs 0 | 0.84 | 0.66 to 1.07 | 0.1539 |
3+4 vs 0 | 0.87 | 0.53 to 1.43 | 0.5741 |
Missing vs 0 | 0.79 | 0.68 to 0.94 | 0.006 |
Distant metastasis | |||
M1b/M1c vs M1a | 0.80 | 0.71 to 0.91 | 0.0005 |
EUS | |||
Yes vs no | 1.49 | 1.22 to 1.82 | 0.0002 |
EBUS | |||
Yes versus no | 1.69 | 1.44 to 1.99 | <0.0001 |
Explorative surgery | |||
Yes versus no | 8.16 | 2.94 to 22.7 | 0.0003 |
Transthoracic biopsy | |||
Yes versus no | 2.08 | 1.67 to 2.60 | <0.0001 |
Unknown versus no | 0.89 | 0.77 to 1.01 | 0.0778 |
Type of systemic therapy | |||
Targeted therapy versus chemo/immunotherapy | 0.78 | 0.68 to 0.89 | 0.0003 |
The hospitals accounted for approximately 8% of the variability in time-to-treatment for stage III (ICC: τ00=0.2815; z(5022)=4.70, p<0.0001) (Median OR lowest-highest: 0.6–1.8) and 4% for stage IV (ICC: τ00=0.1462; z(5253)=4.04, p<0.0001) (Median OR lowest-highest: 0.6–1.7).27
ORs that reached the level of significance are marked as bold.
EBUS, endobronchial ultrasound; EUS, endoscopic ultrasound; ICC, intraclass correlation coefficient.